XML 34 R20.htm IDEA: XBRL DOCUMENT
v3.20.4

Stock-based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Stock-based Compensation | 11. Stock-based Compensation On December 31, 2020, the Company had outstanding stock options, stock awards and SARs awarded under its 2011 Incentive Compensation Plan (2011 Plan). Stock options, stock awards and SARs are currently granted to Company executives and other key employees. In addition, stock awards are currently granted to non-employee directors of the Company. The 2011 Plan authorized the award of 2,600,000 shares of the Company’s common stock for stock options, SARs and stock awards. At December 31, 2020, there were 783,130 shares available for grant under the 2011 Plan. Compensation expense recorded in the consolidated statements of income for all plans was $10,080,000, $8,872,000, and $6,837,000 for the years ended December 31, 2020, 2019 and 2018, respectively. The increase in stock-based compensation in 2020 versus 2019 was primarily due to the increase in compensation expenses related to performance awards. Management’s assessment that higher profitability performance targets for certain grants would be achieved led to the increase of compensation expenses for performance awards. Partially offsetting the increase was the decrease in compensation expenses related to cash SARs. The $16.88 per share increase in the market value of the Company common stock from $102.44 at December 31, 2019 to $119.32 at December 31, 2020 was smaller than the increase of $28.44 per share in the market value of the Company common stock from $74.00 at December 31, 2018 to $102.44 at December 31, 2019. The total income tax benefit recognized in the income statement for share-based compensation arrangements was $2,390,000, $1,501,000, and $1,849,000 for the years ended December 31, 2020, 2019 and 2018, respectively. Stock Options Under all plans, stock option awards are granted with an exercise price equal to the market price of the Company’s stock at the date of grant. The market price is defined and calculated as the average of the opening and closing prices for Company common stock on the grant date as reported in the New York Stock Exchange – Composite Transactions. Stock option awards granted prior to 2017 generally cliff vest after two years. Starting in 2017, stock options have a three-year graded vesting feature, with one-third of the awards vesting each year. The Company has elected the straight-line method of expense attribution for the stock options with graded vesting feature. These options have a 10-year contractual term. The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model incorporating the weighted-average assumptions noted in the following table. Expected volatility is based on the historical volatility of the Company’s stock. The Company also uses historical data to estimate the expected term of options granted. The risk-free rate is the U.S. Treasury note rate that corresponds to the expected option term at the date of grant. The following are the weighted-average assumptions used to calculate the grant-date fair values of stock option awards granted in the years ended December 31, 2020, 2019 and 2018:
|  | For the Years Ended December 31
|  | 2020 |  | 2019 |  | 2018
Expected dividend yield |  | 1.31% |  | 1.32% |  | 1.34%
Expected volatility |  | 26.00% |  | 26.98% |  | 27.41%
Expected term |  | 7.3 years |  | 7.3 years |  | 7.3 years
Risk-free interest rate |  | 1.47% |  | 2.53% |  | 2.88%
A summary of stock option activity for the year ended December 31, 2020 is presented below:
|  | Shares |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Term |  |  | Aggregate Intrinsic Value ($000) |
Options |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Outstanding at January 1, 2020 |  |  | 360,822 |  |  | $ | 66.15 |  |  |  |  |  |  |  |  |
Granted |  |  | 81,924 |  |  |  | 102.06 |  |  |  |  |  |  |  |  |
Exercised |  |  | (48,389 | ) |  |  | 60.47 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (1,807 | ) |  |  | 89.64 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 392,550 |  |  |  | 74.24 |  |  |  | 6.61 |  |  | $ | 17,697 |
Vested or expected to vest at December 31, 2020 |  |  | 385,352 |  |  |  | 73.76 |  |  |  | 6.56 |  |  |  | 17,555 |
Exercisable at December 31, 2020 |  |  | 310,302 |  |  |  | 67.88 |  |  |  | 6.03 |  |  |  | 15,962 |
The weighted-average grant-date fair values of options awarded during the years ended December 31, 2020, 2019 and 2018, were $25.90, $26.49, and $22.13, respectively. The total intrinsic values of options exercised during the years ended December 31, 2020, 2019, and 2018 were $2,534,000, $2,518,000, and $3,879,000, respectively. As of December 31, 2020, the total unrecognized compensation cost for unvested stock options was $1,993,000. That cost is expected to be recognized over a weighted-average period of 1.7 years. Cash received from stock option exercises under the Company’s stock option plans for the years ended December 31, 2020, 2019, and 2018 was $2,926,000, $3,037,000, and $4,163,000, respectively. The actual tax benefit realized for the tax deductions from stock option exercises totaled $339,000, $348,000, and $548,000 for the years ended December 31, 2020, 2019 and 2018, respectively. Stock Awards In 2018, 2019, and 2020, the Company granted stock awards under the 2011 Plan. Most Company stock awards are granted in the form of performance awards. The performance stock awards vest only upon the Company’s achievement of certain Board of Directors approved levels of financial performance by the end of specified measurement periods. The number of Company shares of common stock ultimately distributed, if any, is contingent upon the Company’s actual financial performance attained by the end of the measurement period relative to the Board of Directors approved targets. The fair value of performance stock awards equals the grant-date market price of the Company’s common stock, discounted for the estimated amount of dividends that would not be received during the measurement period. Compensation expense is recorded each reporting period based on the probable number of awards that will ultimately vest given the projected level of financial performance. If at the end of the measurement period the performance objectives are not met, no compensation cost is recognized and any compensation expense recorded in prior periods is reversed. Periodically, the Company also grants stock awards that have no performance conditions associated with their vesting. These stock awards vest based on the service time established for the given grant. In addition, the Company grants stock awards that have no performance conditions associated with their vesting to non-employee directors of the Company. A summary of stock award activity for the year ended December 31, 2020, is presented below:
|  | Shares |  |  | Weighted-Average Grant Date Fair Value |
Stock Awards |  |  |  |  |  |  |  |
Unvested at January 1, 2020 |  |  | 87,334 |  |  | $ | 80.78 |
Granted |  |  | 65,278 |  |  |  | 98.46 |
Vested |  |  | (36,115 | ) |  |  | 70.49 |
Forfeited |  |  | (9,146 | ) |  |  | 84.64 |
Unvested at December 31, 2020 |  |  | 107,351 |  |  |  | 94.66 |
The weighted-average grant-date fair values of stock awards granted during the years ended December 31, 2020, 2019 and 2018, were $98.46, $89.12, and $72.06, respectively. As of December 31, 2020, under the current Company assumption as to the number of stock award shares that will vest at the measurement periods ended December 31, 2021 and 2022, there was $5,313,000 of unrecognized compensation cost for unvested stock awards. That cost is expected to be recognized over a period of 1.8 years. SARs At December 31, 2020, the Company had both cash-settled and Company stock-settled SARs outstanding. SARs granted prior to 2015 are cash-settled, and SARs granted in 2015 and later are stock-settled. SARs granted prior to 2017 cliff vest after two years. Starting in 2017, SARs have a three-year graded vesting feature, with one-third of the awards vesting each year. The Company has elected the straight-line method of expense attribution for the SARs with graded vesting feature. All SARs expire ten years from the grant date. Upon the exercise of a SARs award, a participant receives in cash (for cash-settled SARs) or Company common stock (for stock-settled SARs) an amount that equals the excess of the fair market value of a share of Company common stock at the date of exercise over the fair market value of a share of Company common stock at the date of grant (the exercise price). Cash-settled SARs are accounted for as liabilities that must be re-measured at fair value at the end of every reporting period until settlement. Compensation expense for each reporting period is based on the period-to-period change (or portion of the change, depending on the proportion of the vesting period that has been completed at the reporting date) in the fair value of the SARs. Compensation expense for stock-settled SARs is based on the grant-date value of the awards allocated over the proportion of the vesting period that has been completed at the reporting date. Because stock-settled SARs are considered equity instruments, they are not re-measured at fair value at the end of each reporting period. The following is a summary of SARs activity for the year ended December 31, 2020:
|  | Shares |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Term |  |  | Aggregate Intrinsic Value ($000) |
SARs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Outstanding at January 1, 2020 |  |  | 655,417 |  |  | $ | 68.83 |  |  |  |  |  |  |  |  |
Granted |  |  | 176,330 |  |  |  | 101.96 |  |  |  |  |  |  |  |  |
Exercised |  |  | (172,826 | ) |  |  | 57.32 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (5,423 | ) |  |  | 89.63 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 653,498 |  |  |  | 80.64 |  |  |  | 7.12 |  |  | $ | 25,297 |
The weighted-average grant-date fair values of SARs granted during the years 2020, 2019 and 2018 were $25.88, $26.43, and $22.19, respectively. The fair value for each SARs award was estimated using the Black-Scholes valuation model incorporating the same assumptions as noted for stock options. As of December 31, 2020 and 2019, the liability for cash-settled SARs recorded on the consolidated balance sheet (non-current liabilities) was $2,368,000 and $4,509,000, respectively. At December 31, 2020, there was $4,341,000 of total unrecognized compensation cost related to all unvested SARs. That cost is to be recognized over a weighted-average period of 1.7 years. In general, it is the Company’s policy to issue new shares of its common stock upon the exercise of stock options and stock-settled SARs or the vesting of stock awards.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration